Cutaneous Lupus Erythematosus (CLE) - Epidemiology Forecast - 2034
Description
Key Highlights
CLE is a multifactorial disease involving genetic predisposition and environmental triggers like UV radiation, drugs, pesticides, and tobacco. These factors can cause epigenetic changes—such as altered DNA methylation or histone modification—that dysregulate gene expression and activate the immune system.
CLE encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease.
In 2024, the United States leads the 7MM with approximately 500,000 diagnosed prevalent cases of CLE, driven by greater disease awareness and improved diagnostic capabilities.
In 2024, Japan reported approximately 66 thousand total diagnosed prevalent cases of CLE, which were one of the lowest in the 7MM.
Among the diagnosed patient population in the US, CLE is more prevalent in females (~64%) than in males (~36%), indicating that women are disproportionately affected by the disease.
On the severity basis, mild cases were most common among the CLE patients which is followed by moderate cases.
In conclusion, CLE remains a significant dermatological manifestation of lupus, with the US contributing the highest burden among the 7MM in 2024. The disease predominantly affects females, with mild and chronic forms being the most common.
DelveInsight’s “Cutaneous Lupus Erythematosus (CLE)– Epidemiology Forecast – 2034” report delivers an in-depth understanding of CLE historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Cutaneous Lupus Erythematosus (CLE): Disease Understanding
Cutaneous Lupus Erythematosus (CLE) Overview, and Diagnosis
CLE is a chronic, autoimmune disease affecting the skin, which belongs to the family of lupus erythematosus, where the symptoms are restricted to the skin. Lupus Erythematosus is a chronic, autoimmune disease that affects multiple body organs and systems with a broad spectrum of symptoms.
It is categorized into three main entities: acute cutaneous lupus erythematosus (ACLE), subacute CLE, and chronic cutaneous lupus erythematosus (CCLE). CCLE encompasses discoid LE (DLE), LE profundus (LEP), chilblain LE (CHLE), and LE tumidus (LET).
Diagnosis of CLE requires proper classification of the subtype through a combination of a physical exam, laboratory studies, histology, antibody serology, and occasionally direct immunofluorescence while ensuring to exclusion of systemic disease.
Cutaneous Lupus Erythematosus (CLE) Epidemiology
The CLE epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Cutaneous Lupus Erythematosus epidemiology is segmented with detailed insights into total diagnosed prevalent cases of CLE, diagnosed prevalent cases of CLE by gender, diagnosed prevalent cases of CLE by type, and diagnosed prevalent cases of CLE by severity.
The total diagnosed prevalent cases of CLE in the 7MM comprised of approximately ~800 thousand cases in 2024.
According to the findings, approximately two-thirds of people with lupus will develop some type of skin disease Cutaneous Lupus Erythematosus, and about 2% of SLE cases eventually develop CLE every year.
It has been observed that the prevalence of chronic CLE is higher among the diagnosed population when compared to other types in the 7MM. The chronic CLE accounted for ~350 thousand cases in the US in 2024.
Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases followed by France and Spain accounted for the lowest number of cases with ~40 thousand cases.
Scope of the Report
The report covers a segment of an executive summary, and a descriptive overview of CLE explaining its causes, signs and symptoms, pathogenesis.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Cutaneous Lupus Erythematosus (CLE) Report Insights
Patient Population
Country-wise Epidemiology Distribution
Cutaneous Lupus Erythematosus (CLE) Report Key Strengths
Ten-year Forecast
The 7MM Coverage
CLE Epidemiology Segmentation
Cutaneous Lupus Erythematosus (CLE) Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of CLE? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CLE?
What is the historical and forecasted CLE patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of CLE?
Which clinical factors will affect CLE?
Which factors will affect the increase in the diagnosis of CLE?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in CLE cases in varying geographies over the coming years.
A detailed overview of Total diagnosed prevalent cases of CLE, Diagnosed prevalent cases of CLE by gender, Diagnosed prevalent cases of CLE by type, and diagnosed prevalent cases of CLE by severity, is included.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
CLE is a multifactorial disease involving genetic predisposition and environmental triggers like UV radiation, drugs, pesticides, and tobacco. These factors can cause epigenetic changes—such as altered DNA methylation or histone modification—that dysregulate gene expression and activate the immune system.
CLE encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease.
In 2024, the United States leads the 7MM with approximately 500,000 diagnosed prevalent cases of CLE, driven by greater disease awareness and improved diagnostic capabilities.
In 2024, Japan reported approximately 66 thousand total diagnosed prevalent cases of CLE, which were one of the lowest in the 7MM.
Among the diagnosed patient population in the US, CLE is more prevalent in females (~64%) than in males (~36%), indicating that women are disproportionately affected by the disease.
On the severity basis, mild cases were most common among the CLE patients which is followed by moderate cases.
In conclusion, CLE remains a significant dermatological manifestation of lupus, with the US contributing the highest burden among the 7MM in 2024. The disease predominantly affects females, with mild and chronic forms being the most common.
DelveInsight’s “Cutaneous Lupus Erythematosus (CLE)– Epidemiology Forecast – 2034” report delivers an in-depth understanding of CLE historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Cutaneous Lupus Erythematosus (CLE): Disease Understanding
Cutaneous Lupus Erythematosus (CLE) Overview, and Diagnosis
CLE is a chronic, autoimmune disease affecting the skin, which belongs to the family of lupus erythematosus, where the symptoms are restricted to the skin. Lupus Erythematosus is a chronic, autoimmune disease that affects multiple body organs and systems with a broad spectrum of symptoms.
It is categorized into three main entities: acute cutaneous lupus erythematosus (ACLE), subacute CLE, and chronic cutaneous lupus erythematosus (CCLE). CCLE encompasses discoid LE (DLE), LE profundus (LEP), chilblain LE (CHLE), and LE tumidus (LET).
Diagnosis of CLE requires proper classification of the subtype through a combination of a physical exam, laboratory studies, histology, antibody serology, and occasionally direct immunofluorescence while ensuring to exclusion of systemic disease.
Cutaneous Lupus Erythematosus (CLE) Epidemiology
The CLE epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. The Cutaneous Lupus Erythematosus epidemiology is segmented with detailed insights into total diagnosed prevalent cases of CLE, diagnosed prevalent cases of CLE by gender, diagnosed prevalent cases of CLE by type, and diagnosed prevalent cases of CLE by severity.
The total diagnosed prevalent cases of CLE in the 7MM comprised of approximately ~800 thousand cases in 2024.
According to the findings, approximately two-thirds of people with lupus will develop some type of skin disease Cutaneous Lupus Erythematosus, and about 2% of SLE cases eventually develop CLE every year.
It has been observed that the prevalence of chronic CLE is higher among the diagnosed population when compared to other types in the 7MM. The chronic CLE accounted for ~350 thousand cases in the US in 2024.
Among EU4 and the UK, the UK accounted for the highest number of diagnosed prevalent cases followed by France and Spain accounted for the lowest number of cases with ~40 thousand cases.
Scope of the Report
The report covers a segment of an executive summary, and a descriptive overview of CLE explaining its causes, signs and symptoms, pathogenesis.
Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.
Cutaneous Lupus Erythematosus (CLE) Report Insights
Patient Population
Country-wise Epidemiology Distribution
Cutaneous Lupus Erythematosus (CLE) Report Key Strengths
Ten-year Forecast
The 7MM Coverage
CLE Epidemiology Segmentation
Cutaneous Lupus Erythematosus (CLE) Report Assessment
Epidemiology Segmentation
Current Diagnostic Practices
FAQs
Epidemiology Insights
What are the disease risks, burdens, and unmet needs of CLE? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CLE?
What is the historical and forecasted CLE patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What is the diagnostic pattern of CLE?
Which clinical factors will affect CLE?
Which factors will affect the increase in the diagnosis of CLE?
Reasons to buy
Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the change in CLE cases in varying geographies over the coming years.
A detailed overview of Total diagnosed prevalent cases of CLE, Diagnosed prevalent cases of CLE by gender, Diagnosed prevalent cases of CLE by type, and diagnosed prevalent cases of CLE by severity, is included.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
60 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Cutaneous Lupus Erythematosus (CLE) Patient Overview at a Glance
- 3.1. Patient Share Distribution (%) in the 7MM in 2024
- 3.2. Patient Share Distribution (%) in the 7MM in 2034
- 4. Executive Summary
- 5. Epidemiology Forecast Methodology
- 6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Signs and Symptoms
- 6.3. Causes
- 6.4. Diagnosis and Differential Diagnosis
- 6.4.1. Diagnostic Algorithm
- 6.4.2. Differential Diagnosis
- 6.4.3. Diagnostic Guidelines
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale
- 7.3. Total Diagnosed Prevalent Cases of CLE in the 7MM
- 7.5. The United States
- 7.5.1. Total Diagnosed Prevalent Cases of CLE in the United States
- 7.5.2. Diagnosed prevalent cases of CLE by gender in the United States
- 7.5.3. Diagnosed prevalent cases of CLE by type in the United States
- 7.5.4. Diagnosed prevalent cases of CLE by severity in the United States
- 7.6. EU4 and the UK
- 7.6.1. Total Diagnosed Prevalent Cases of CLE in EU4 and the UK
- 7.6.2. Diagnosed Prevalent Cases of CLE by gender in EU4 and the UK
- 7.6.3. Diagnosed Prevalent Cases of CLE by type in EU4 and the UK
- 7.6.4. Diagnosed Prevalent Cases of CLE by severity in EU4 and the UK
- 7.7. Japan
- 7.7.1. Total Diagnosed Prevalent Cases of CLE in Japan
- 7.7.2. Diagnosed Prevalent Cases of CLE by gender in Japan
- 7.7.3. Diagnosed Prevalent Cases of CLE by type in Japan
- 7.7.4. Diagnosed Prevalent Cases of CLE by severity in Japan
- 8. KOL Views
- 9. Appendix
- 9.1. Acronyms and Abbreviations
- 9.2. Bibliography
- 9.3. Report Methodology
- 10. DelveInsight Capabilities
- 11. Disclaimer
- 12. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
